Closed Incisional Management

IHT®’s unique advanced wound care and NPWT solutions for incisional management provide protection against post-surgical incisional complications through the combined use of: PhaseOne® hypochlorous (HOCl) solution and Sorbact® microbe-binding advanced wound care dressings.


Consider using PhaseOne® for irrigation of the surgical pocket prior to closure followed by Sorbact® Surgical Dressing.

High Risk Patients

For patients with high risk of post-surgical complications, such as patients with a history of diabetes, COPD, chronic corticosteroid use, or morbid obesity, our NewEra® NPWT system provides incisional NPWT to decrease risk of seroma, hematoma, SSI, and dehiscence.1

PhaseOne® Skin and Wound Cleanser (235 mL) (40mL)

A fast-acting skin and wound cleanser, PhaseOne® penetrates and disrupts biofilm, killing bacteria and fungi, as well as neutralizes resulting toxins*. Formulated as a pure concentration of hypochlorous acid (HOCl) in saline, PhaseOne® is made without the toxic bleach and other preservative chemicals found in other products, making it gentle, non-irritating, and non-sensitizing to skin and new tissue.

PhaseOne® may be used for routine cleansing and irrigation and supports debridement of:

  • Intraoperative pocket lavage, before subcutaneous closure
  • Stage I to IV pressure injuries
  • Stasis ulcers
  • Leg ulcers
  • Diabetic foot ulcers
  • First-degree and second-degree burns
  • Post-surgical wounds
  • Grafted and donor sites
  • Minor burns, superficial abrasions, and wounds
  • Moistening absorbent wound dressings

*= In vitro data.  Hypochlorous acid in PhaseOne® serves as a preservative in solution.  Refer to Instructions for use for organisms tested in solution.

Sorbact® Surgical Dressing

Sorbact® Surgical Dressing is a sterile, microbe-binding, self-adherent wound dressing. It consists of a green Sorbact® wound contact layer combined with an absorbent wound pad and a transparent acrylic adhesive film. Sorbact® Surgical Dressing absorbs and retains exudate and ensures a moist wound environment. The waterproof backing film provides protection against external contamination and allows excess fluid to evaporate.

NewEra® I NPWT Pump:

The NewEra® I NPWT pump is designed for use by healthcare professionals in acute care settings or those wounds with high output exudate. It is equipped with touch screen controls, options of continuous vs. intermittent suction settings, leak alarm, tube blockage alarm, canister full alarm, as well as a screen lock feature. It comes standard with a 1000cc canister and tube clamps to avoid exudate spillage. The canister has overflow capabilities to prevent fluid reflux into the wound and to block fluid passage into the pump when canister is full. Battery life is up to 24 hours. Screen displays both time to battery exhaustion (when unplugged) and time to full charge (when plugged into a power source).

The Cost-Effective Way to Prevent Surgical Site Infections

Surgical site infections are the most common and costly of all hospital acquired infections (HAI)2.

SSI encompass 20% of all HAI, leading to an increased length of stay by 9.7 days and an annual cost to the U.S. healthcare system of $3.5-$10 billion2.

It is estimated that 60% of SSI are preventable using evidence-based measures2.

A randomized, controlled study done by Stanirowski, et al, found that using Sorbact® Surgical dressings after cesarean section reduced SSI as compared standard surgical dressing3.

    1. Brindle CT, Creehan SM. Management of Surgical Wounds. In: Doughty DB, McNichol LL, eds. WOCN Core Curriculum: Wound Management. Philadelphia, PA: Wolters Kluwer; 2016.
    2. Ban, KA et al., American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. J Am Coll Surg, DOI:
    3. Stanirowski, Pawel, et al. “Randomized Controlled Trial Evaluating Dialkylcarbamoyl Chloride Impregnated Dressings for the Prevention of Surgical Site Infections in Adult Women Undergoing Cesarean Section.” Surgical Infections, vol. 17, no. 4, 2016, pp. 427–435., doi:10.1089/sur.2015.223.

*=Results derived from in vitro testing of HOCl in solution. Data on file.